Google
 

Archive for the ‘Cancer / Oncology’ Category

Poniard To Present Clinical Data From Picoplatin Trials In Multiple Tumor Types At American Society Of Clinical Oncology 2008 Annual Meeting

Friday, May 16th, 2008

Poniard Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on oncology, announced that the Company will present data from three clinical trials of picoplatin, in various tumor types and combinations, at poster sessions during the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO) at McCormick ...

Release Of Cytopia Abstract For CYT997 Oral Presentation At American Society Of Clinical Oncology

Friday, May 16th, 2008

Cytopia Limited (ASX: CYT) announced that the abstract for its upcoming oral presentation on CYT997 at the 2008 Annual Meeting of the American Society of Clinical Oncology (ASCO) will be accessible to the public via ASCO's website (http://www.asco.org) from 9pm on Thursday 15 May (US EDT). ...

How Tumorigenesis And Drug Design Are Affected By Mutant P53 Stability

Friday, May 16th, 2008

In the May 15th issue of G&D, Dr. Guillermina Lozano (MD Anderson Cancer Center) and colleagues reveal how the stabilization of a mutated form of p53 affects oncogenesis, and lends startling new insight into the potential pitfalls of using Mdm2 inhibitors for cancer therapy."Our data are both exciting and sobering: ...

New Hope For UK Follicular Lymphoma Patients As Zevalin(R), [90Y]-ibritumomab Tiuxetan, Licenced For First Line Consolidation Therapy

Friday, May 16th, 2008

Zevalin ([90Y]-ibritumomab tiuxetan) can now be used as first-line consolidation therapy after remission induction in previously untreated patients with follicular lymphoma (FL).1The European Commission (EC) decision is based on data from the First-line Indolent Trial (FIT) study which showed almost a 2 year improvement in progression free survival (PFS) in ...

`Early Warning’ For Oral Cancer Now Covered Under UnitedHealthcare Specialty Benefits Dental Plans

Friday, May 16th, 2008

UnitedHealthcare Specialty Benefits now provides coverage under all of its insured dental plans for a new oral cancer screening test for potential abnormalities inside the mouth, including premalignant lesions and oral cancer. The test, which uses light-contrast technology, can improve a dentist's ability to identify, evaluate and monitor lesions that ...

Phase II Study Of IMC-A12 For Advanced Liver Cancer Opens For Patient Enrollment

Friday, May 16th, 2008

ImClone Systems Incorporated (NASDAQ: IMCL), a global leader in the development and commercialization of novel antibodies to treat cancer, today announced that a Phase II clinical trial of IMC-A12, ImClone's fully human, IgG1 anti-insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody, in patients with advanced hepatocellular cancer (liver cancer) has opened ...

Sunbed Regulations Useless Says Scottish Parliament Health Committee

Friday, May 16th, 2008

A health committee of the Scottish parliament said the regulations covering sunbeds and tanning machines offered for public use in commercial parlours are "useless" and do not protect the public, after reviewing evidence from the industry, environmental health and medical research. The committee is reviewing the control of tannning ...

Study Says New Radiation Therapy Technology For Breast Cancer Helps Protect Tissue, Adds Options For Patients

Friday, May 16th, 2008

New research conducted at Moores Cancer Center at University of California, San Diego shows that the SAVI™ breast brachytherapy applicator, a new approach for delivering accelerated partial breast irradiation (APBI), may provide better protection of healthy tissue than other partial breast irradiation methods. The research team, led by Catheryn Yashar, ...

Study Shows That Prostate Cancer Increases The Risk Of Bone Fracture

Friday, May 16th, 2008

As unlikely as it sounds, scientists at the Garvan Institute for Medical Research have shown that there is a link between prostate cancer and a higher risk of bone fracture. Analysis of data from Garvan's Dubbo Osteoporosis Epidemiology Study suggests that men with prostate cancer face a 50% higher risk ...

Connecting Cancer Genes - Study Implicates 350 Gene Regions In Cancer Development In The Mouse, UK

Friday, May 16th, 2008

A large genetic study in mice has identified hundreds of genes involved in the development of cancer by examining the DNA of more than 500 lymphomas to find the cancer causing mutations. The study found just over 10,000 mutations in total, which together implicate almost 350 regions in the mouse ...

“Cool” New Treatment For Hot Flashes In Breast Cancer Survivors

Friday, May 16th, 2008

An anesthetic injection into a collection of nerves in the neck of breast cancer survivors may reduce the severity and frequency of debilitating hot flashes and night awakenings associated with breast cancer treatment, according to a new study published online by The Lancet Oncology and appearing in its June ...

31 Million Dollars Allocated To National Breast And Ovarian Cancer Centre To Improve Access To Breast Prostheses, Australia

Friday, May 16th, 2008

National Breast and Ovarian Cancer Centre has welcomed an additional $31 million funding over five years from the Australian Government to allow all Australian women who have had a mastectomy as a result of breast cancer to access external prostheses. This Federal budget measure will ...

Science Briefs From Weill Cornell Medical College

Friday, May 16th, 2008

Stem Cells Might Contribute to Vascular Disease - Stem Cells Might Cause More Damage After Vascular SurgeryPhysician-scientists believe that stem cells might play a harmful role in the body's reaction to trauma following common vascular surgery, like angioplasty. A team of scientists - led by Dr. K. Craig Kent, Greenberg-Starr ...

Chemotherapy Does Not Improve Treatment For Mesothelioma

Friday, May 16th, 2008

For mesothelioma patients, the addition of chemotherapy to the usualactive symptom control (ASC) does not appear to improve survival orquality of life, according to an article released on May 16, 2008 in TheLancet. Malignant pleural mesothelioma (MPM) is cancer of the mesothelium, theprotective layer that covers the lungs. Generally associated ...

Survivors Of Childhood Cancers Treated With Cyclophosphamide More Likely To Develop Bladder Cancer Later In Life

Friday, May 16th, 2008

Survivors of childhood cancers treated with the chemotherapy drug cyclophosphamide were five times more likely to develop bladder cancer later in life than the general population. Results of this new research from the United Kingdom were presented during the Annual Scientific Meeting of the American Urological Association (AUA). Survivors originally ...